Genomic Kidney Care: Invest in Decision Yield, Not Test Volume

01 / THE ARGUMENT

The service begins with a clinical question

A kidney-genetics program should start with the decision a result could change. Is the etiology uncertain? Could a diagnosis alter treatment, surveillance, transplant evaluation or family counseling? The answer determines the clinical assessment, appropriate test and receiving expertise. My thesis is that a service selling test capacity without funding interpretation and follow-through sells an intermediate product. Its defensible unit of value is a documented decision that the patient and treating team can use.

KDIGO includes genetics within evaluation of CKD cause and discusses situations where testing may be particularly informative, alongside the importance of counseling and interpretive expertise. This supports a clinically governed pathway, not indiscriminate sequencing. A negative finding can leave a clinical question unresolved, and a variant of uncertain significance requires careful interpretation. Neither should be automatically coded as a definitive molecular diagnosis or a failure of the laboratory. The service must preserve these distinctions in its records. [4]

02 / THE ARGUMENT

Yield is conditional on who enters the pathway

Schott and colleagues’ systematic review included 60 studies and 10,107 adults. Pooled diagnostic yield was 40%, with a 95% confidence interval of 33% to 46%; cystic disease had higher yield. The authors emphasize clinically selected populations and heterogeneity in cohorts and testing methods. This is informative evidence for targeted evaluation, not a forecast that two in five people in an unselected CKD panel will receive a molecular diagnosis. [1]

A 2026 study by Merz and colleagues evaluated 256 patients with suspected inherited kidney disease, including adults and children, at one tertiary center. Pathogenic variants were found in 38.7%, with yields differing across disease categories. Its selected population and single-center design matter as much as its headline percentage. A service should therefore maintain its own denominator by referral indication and testing approach. Comparing laboratories or clinics without adjusting those differences can mistake selection for technical superiority. [3]

03 / THE ARGUMENT

Clinical utility and clinical outcomes need separate ledgers

The one-year RenaCARE report by Chebib and colleagues examined broad-panel testing in a prospective, single-arm multicenter study. Of 1,388 patients, 335 had a positive finding; 1,174 had a completed one-year questionnaire. Clinicians reported helpfulness or a management change for 86% of positive findings and 42% of negative findings. Those categories measure reported utility, not randomized reductions in kidney failure or total cost. The study used a commercial panel and includes substantial manufacturer involvement. [2]

Management utility is still strategically important when it is documented precisely. A result may refine diagnosis, prompt surveillance, inform a donor assessment, guide family counseling or change the consideration of a supported therapy. Each has different downstream resources and consequences. Record the decision, the evidence supporting it and whether it was actually implemented. A report that could influence care, a recommendation made by a clinician and a completed change in care are three distinct milestones.

04 / THE ARGUMENT

Treatment eligibility is a gate, not a synonym for positivity

A positive finding does not imply that a targeted drug is available or appropriate. Treatment eligibility depends on the condition, variant interpretation, phenotype, disease stage and applicable therapeutic evidence. The operational pathway should connect the interpreting team to the treating specialist and pharmacy only when a supported clinical action exists. For other findings, useful decisions may concern surveillance or counseling. Commercial reporting should disclose these categories rather than inflate an actionability rate by blending fundamentally different benefits.

The referral packet needs enough clinical context for that decision: family history, disease course, relevant laboratory or imaging results, prior investigations and the question being asked. Assign responsibility for returning the result and handling uncertain or incidental findings. Family members are separate people with their own choices; cascade testing requires an appropriate counseling and consent pathway. The program should be able to close a case with an explained unresolved result without manufacturing a treatment opportunity.

05 / THE ARGUMENT

Underwrite the complete decision pathway

A finance model should include clinical triage, the assay, counseling, interpretation, specialist follow-up and any justified downstream care. Track cost per interpreted result and cost per implemented management decision as separate operating measures. They cannot establish cost-effectiveness by themselves. Claimed savings from avoided investigations or changed therapy need documented counterfactuals, actual costs and a credible method for attributing the difference. Clinician-reported helpfulness is not a payable financial outcome.

A disciplined pilot compares its observed referral mix, diagnostic yield and decision completion with its planned pathway before expanding. It also audits who is never referred, who cannot complete testing and who receives a result without follow-up. The next investment may be a counseling appointment or specialist review rather than a larger panel. Genomic kidney care earns strategic value when it resolves clinically meaningful uncertainty and makes the resulting decision feasible, while keeping unproven outcome and economic claims visible.

FROM EVIDENCE TO ALLOCATION

The operating and investment case

Proposed design by Azis R. Dabas. These decisions and evaluation criteria are not outcomes established by the cited studies.

Decision: Fund a clinically selected kidney-genetics service with interpretation and follow-up capacity. Require a stated pretest question and a documented post-test decision before treating assay volume as evidence of service value.
Accountable owner: Nephrology service-line director with medical genetics or genetic counseling leadership, an interpreting clinical team, pharmacy for supported treatment pathways and a finance partner.

The delivery sequence

Triage the referral by phenotype, prior assessment and the clinical question.
Provide appropriate counseling and consent, then select the testing approach.
Interpret the result with clinical context and record diagnostic certainty.
Return the result and document treatment, surveillance, transplant, family-counseling or unresolved decisions.
Confirm implementation and audit access, turnaround, decision yield and full pathway cost.

The economics

Measure all costs from referral through result return and justified follow-up. Diagnostic yield is the share with a supported molecular diagnosis; decision yield is the share with a documented appropriate management decision. Track both without equating either to avoided kidney failure. Estimate incremental savings only for specifically documented avoided actions or changed resource use against a credible comparator.

The measures that govern expansion

Referral appropriateness and completeness
Result-return and counseling completion
Diagnostic yield by clinical indication and testing method
Implemented management decisions by type
Time from referral to usable decision
Uncertain results with a documented follow-up plan
Access differences and cost of the complete pathway

Stop or redesign when

Pause expansion if interpretation or counseling capacity cannot keep pace, if uncertain variants are being treated as definitive diagnoses, or if commercial treatment and savings claims exceed the evidence for the actual disease and population.

THE EVIDENCE LEDGER

What supports the argument

Study findings, policy requirements and market signals support different claims. Their boundaries remain visible.

[1] peer-reviewed · September 19, 2024

Utility of Genetic Testing in Adults with CKD: A Systematic Review and Meta-Analysis

Design or status: Systematic review and meta-analysis; online September 19, 2024, January 1, 2025 issue
Verified finding: Across 60 studies and 10,107 adults, pooled diagnostic yield was 40% (95% CI 33–46); yield depended on phenotype and clinical selection.
Boundary: Selected cohorts, heterogeneous technologies and reporting limit generalization to unselected CKD populations. Utility evidence was much more limited than yield evidence.

[2] peer-reviewed · October 29, 2025

Genetic Testing in the Management of Adult CKD

Design or status: Prospective single-arm multicenter clinical-utility follow-up; online October 29, 2025, April 1, 2026 issue
Verified finding: Among 1,388 patients, 335 had positive findings; one-year questionnaires were completed for 1,174. Clinicians reported helpfulness or management change in 86% of positive and 42% of negative findings.
Boundary: No randomized comparator; clinician-reported utility and prognosis, incomplete follow-up, commercial-panel use and manufacturer involvement do not establish improved hard outcomes or cost savings.

[3] peer-reviewed · July 2026

Clinical impact of genetic testing in inherited kidney diseases

Design or status: Single-tertiary-center cohort of suspected inherited disease; July 2026 issue verified
Verified finding: Pathogenic variants were identified in 38.7% of 256 selected patients, including 175 adults and 81 children; diagnostic yield varied by phenotype.
Boundary: Selected single-center population and observational kidney-survival comparisons do not establish the causal benefit or economic return of testing.

[4] policy · April 2024

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Design or status: Evidence-based clinical practice guideline
Verified finding: Classifies CKD by cause, GFR and albuminuria and incorporates evaluation of cause, including genetic testing and access to genetic counseling when appropriate.
Boundary: A guideline establishes a clinical framework; it does not establish the financial return of a particular implementation program.

FOLLOW THE SOURCE

Sources and editorial method

Selected evidence was reviewed through October 7, 2026. Numbered references connect claims to their underlying records. Economic mechanisms and business cases are the author’s analysis unless a source is cited. The review is selective; publication dates retain the precision available in the source.

Utility of Genetic Testing in Adults with CKD: A Systematic Review and Meta-Analysis
Clara Schott, Victoria Lebedeva, Cambrie Taylor, Saeed Abumelha, Pavel S. Roshanov, Dervla M. Connaughton. Clinical Journal of the American Society of Nephrology. September 19, 2024. peer-reviewed.
DOI: 10.2215/CJN.0000000000000564 · Primary verification record · Consensus paper record
Consensus citation count at retrieval: 18. This dated index count is not a measure of study quality.
Genetic Testing in the Management of Adult CKD
Fouad T. Chebib, Xiangling Wang, Suneel M. Udani, Maggie Westemeyer, Dinah Clark, Zhiji Zhang, Michelle S. Bloom, Hila Milo Rasouly, Victoria Kolupaeva, Mohammad R. Mizani, Neville R. Dossabhoy, Arman Faravardeh, Zachary P. Demko, Sri Kotte, Sumit Punj, Steven L. Chapman, Matthew Rabinowitz, Ronen Schneider, Hossein Tabriziani, Sangeeta Bhorade, Ali G. Gharavi, Neera K. Dahl. Journal of the American Society of Nephrology. October 29, 2025. peer-reviewed.
DOI: 10.1681/ASN.0000000913 · Primary verification record · Consensus paper record
Consensus citation count at retrieval: 4. This dated index count is not a measure of study quality.
Clinical impact of genetic testing in inherited kidney diseases
Lea M. Merz, Sarah Stopp, Ilona Krey, Fabian Baalmann, Emilia Marczak, Nora Liebmann, Olga Hempel, Bastian M. Krüger, Marie Engesser, Anne-Christin Teichmann, Franziska Schnabel, Rami A. Jamra, Johannes R. Lemke, Carsten Bergmann, Tom H. Lindner, Jonathan de Fallois, Johannes Münch, J. Halbritter, Katalin Dittrich, Friederike Petzold. Clinical Kidney Journal. July 2026. peer-reviewed.
DOI: 10.1093/ckj/sfag160 · Primary verification record · Consensus paper record
Consensus citation count at retrieval: 0. This dated index count is not a measure of study quality.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
KDIGO CKD Work Group. Kidney International. April 2024. policy.
DOI: 10.1016/j.kint.2023.10.018 · Primary verification record

Study authors retain credit for their work. Researcher affiliations and publisher names do not imply affiliation with or endorsement of this analysis.